Glenmark’s innovative pipeline is focused on three core therapeutic areas: oncology, dermatology and respiratory. Our pipeline demonstrates our efforts to solve some of medicine’s most difficult challenges and discover molecular entities that will have a major impact on how people live.
With more than 350 scientists dedicated to new chemical entity (NCE) research and more than 100 scientists involved in new biologic entity (NBE) research, we have developed an enviable and robust pipeline anchored in first- and best-in-class discovery. With 4 NBEs, 3 NCEs and a biosimilar candidate in various stages of clinical development, Glenmark is delivering on its commitment to bring the best science to patients worldwide.
To find more about the Glenmark Pharmaceuticals Ltd pipeline click here
To find out more about the Ichnos Sciences pipeline click here